There are 2934 resources available
Conclusions
Presenter: Stefan Bielack
Session: ESMO-SIOPE/AYA Collaborative session: Genetics and precision medicine for AYA with cancer
Resources:
Slides
Webcast
Aggressive B-cell lymphomas
Presenter: Marek Trneny
Session: Management of lymphomas in light of the updated WHO classification
Resources:
Slides
Webcast
T-cell lymphomas
Presenter: Francesco D'Amore
Session: Management of lymphomas in light of the updated WHO classification
Resources:
Slides
Webcast
5016 - Lefitolimod vs standard of care (SOC) for patients with metastatic colorectal cancer (mCRC) responding to first-line standard treatment: Results from the randomized phase 3 IMPALA trial
Presenter: Ramon Salazar
Session: Proffered Paper 2 – Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
Proffered Paper 2 – Gastrointestinal tumours, colorectal - Invited Discussant LBA32, LBA33 and 524O
Presenter: Alfredo Falcone
Session: Proffered Paper 2 – Gastrointestinal tumours, colorectal
Resources:
Slides
Webcast
Proffered Paper 2 – Gastrointestinal tumours, colorectal - Invited Discussant LBA34
Presenter: Andrew Chan
Session: Proffered Paper 2 – Gastrointestinal tumours, colorectal
Resources:
Slides
Webcast
5378 - 2nd/3rd-line Nivolumab vs Nivo plus Ipilimumab in Malignant Pleural Mesothelioma: long-term results of IFCT-1501 MAPS2 phase 2R trial with a focus on hyperprogression (HPD)
Presenter: Gerard Zalcman
Session: Proffered Paper 2 – Non-metastatic NSCLC and other thoracic malignancies (mesothelioma and thymic carcinoma)
Resources:
Abstract
Slides
Webcast
1316 - SAKK 17/16: Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm Phase II trial.
Presenter: Yannis Metaxas
Session: Proffered Paper 2 – Non-metastatic NSCLC and other thoracic malignancies (mesothelioma and thymic carcinoma)
Resources:
Abstract
Slides
Webcast
803 - Durable anti-tumor activity of the multi-targeted inhibitor lenvatinib in patients with advanced or metastatic thymic carcinoma; Preliminary results from a multicenter phase II (REMORA) trial.
Presenter: Shoichi Itoh
Session: Proffered Paper 2 – Non-metastatic NSCLC and other thoracic malignancies (mesothelioma and thymic carcinoma)
Resources:
Abstract
Slides
Webcast
Conclusions and perspectives
Presenter: Joaquim Bellmunt
Session: Selecting and sequencing therapy in previously untreated urothelial cancer
Resources:
Slides
Webcast